















































































































acute destabilized heart failure: an international pooled analysis of 1256 patients: the International Collaborative of NT-proBNP Study. *Eur Heart J.* 2006;27(3):330-7.

**75.** Quiroga B, Goicoechea M, Garcia de Vinuesa S, Verde E, Verdalles U, Yuste C, et al. [Cardiac markers in different degrees of chronic kidney disease: influence of inflammation and previous heart disease]. *Med Clin (Barc).* 2012;139(3):98-102.

**76.** Nunez J, Minana G, Nunez E, Chorro FJ, Bodi V, Sanchis J. Clinical utility of antigen carbohydrate 125 in heart failure. *Heart Fail Rev.* 2014;19(5):575-84.

**77.** Kanno N, Hori Y, Hidaka Y, Chikazawa S, Kanai K, Hoshi F, et al. Plasma atrial natriuretic peptide and N-terminal pro B-type natriuretic peptide concentrations in dogs with right-sided congestive heart failure. *J Vet Med Sci.* 2016;78(4):535-42.

**78.** Toufan M, Namdar H, Abbasnezhad M, Habibzadeh A, Esmaeili H, Yaraghi S, et al. Diagnostic Values of Plasma, Fresh and Frozen Urine NT-proBNP in Heart Failure Patients. *J Cardiovasc Thorac Res.* 2014;6(2):111-5.

**79.** Nunez J, Nunez E, Bayes-Genis A, Fonarow GC, Minana G, Bodi V, et al. Long-term serial kinetics of N-terminal pro B-type natriuretic peptide and carbohydrate antigen 125 for mortality risk prediction following acute heart failure. *Eur Heart J Acute Cardiovasc Care.* 2016.

**80.** Ordu S, Ozhan H, Alemdar R, Aydin M, Caglar O, Yuksel H, et al. Carbohydrate antigen-125 and N-terminal pro-brain natriuretic peptide levels: compared in heart-failure prognostication. *Tex Heart Inst J.* 2012;39(1):30-5.

**81.** National Clinical Guideline Centre. Acute heart failure: diagnosing and managing acute heart failure in adults. London (UK): National Institute for Health and Care Excellence (NICE); 2014 Oct. [Consulta: 17/02/2017].

**82.** Yancy CW, Jessup M, Bozkurt B, Butler J, Casey DE Jr, Drazner MH, Fonarow GC, Geraci SA, Horwich T, Januzzi JL, Johnson MR, Kasper EK, Levy WC, Masoudi FA, McBride PE, McMurray JJ, Mitchell JE, Peterson PN, Riegel B, Sam F, Stevenson LW, Tang WH, Tsai EJ, Wilkoff BL. 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. *J Am Coll Cardiol.* 2013 Oct 15;62(16):e147-239.

**83.** Chronic Heart Failure - Diagnosis and Management. British Columbia Guidelines. Octubre 2015.

- 84.** Morales Rull J. L. Valor pronóstico de NT-proBNP y cistatina plasmáticos en pacientes con insuficiencia cardíaca crónica agudizada. Zaragoza: Universidad de Zaragoza; 2012. 179 p.
- 85.** Anwaruddin S, Lloyd-Jones DM, Baggish A, Chen A, Krauser D, Tung R, et al. Renal function, congestive heart failure, and amino-terminal pro-brain natriuretic peptide measurement: results from the ProBNP Investigation of Dyspnea in the Emergency Department (PRIDE) Study. *J Am Coll Cardiol.* 2006;47(1):91-7.
- 86.** Bruch C, Fischer C, Sindermann J, Stypmann J, Breithardt G, Gradaus R. Comparison of the prognostic usefulness of N-Terminal Pro-Brain Natriuretic Peptide in Patients with heart failure with versus without chronic kidney disease. *Am J Cardiol* 2008;102:469–474.

